[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Parkinson’s Disease Drugs Market to See Moderate Growth to 2022, Projects RNCOS in Its Topical Report Available at MarketPublishers.com

05 Sep 2017 • by Natalie Aster

LONDON – Globally, the market for Parkinson’s disease (PD) drugs is poised for a moderate growth pace through to 2022. The forces stimulating the market growth encompass the rising awareness about the disease and its treatment modalities, research grants and funding, among others.

However, expensiveness of treatment and expiring patents are some of the stumbling blocks of the global PD drugs marketplace.

Amongst the types of treatments discussed, levodopa therapy is the first and most efficacious treatment for the Parkinson’s disease. The advantages of the drug are observed shortly after administration. Meantime, stem cell therapy is a developing field that utilises stem cells to treat or prevent a condition/disease, comprising Parkinson’s disease. Even a small success from this procedure can lead to considerable enhancements in patients’ quality of life.

Multiple companies, like International Stem Cell Corp and SanBio, are performing clinical trials for stem cell therapies to treat PD. Therefore, stem cell therapy opens up enormous opportunities for the PD drugs market growth in the foreseeable future.

With respect to geography, North America grabbed the lion’s share in the overall PD drugs sector in 2016.

Topical research report “Global Parkinson’s Disease Drugs Market Outlook 2022” elaborated by RNCOS E-Services offers an all-round, unbiased evaluation of the market worldwide, covering its current landscape and future performance.

The report provides insights into the major drivers and challenges, highlights various opportunities for growth of the world PD drugs market. The study provides market segmentation by treatment type, and based on geography. It sheds light on the trends and developments, mergers and acquisitions, leading products in Parkinson’s disease market. The study offers a discussion of the dominant players active in the global Parkinson’s disease drugs market, giving an overview of their businesses and financials, casting light on their recent developments, alongside their product ranges and drug pipeline. Detailed market outlook to 2022 is also included in the report.

Other topical research reports prepared by RNCOS E-Services are available at its page at MarketPublishers.com. 


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest